US › Healthcare

GT Biopharma Inc (GTBP)

US · Healthcare · Biotechnology

$7.49-4.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-4.5M

EPS

$-0.12

EPS estimate

$-0.08

EPS came in at -0.12 against a street estimate of -0.08 — a miss of 50.0%.

Key statistics

Market cap

$21.0M

P/E

0.1

Forward P/E

17.3

P/B

4.30

Book value

$2.00

EPS (TTM)

$130.25

52-week high

$11.98

52-week low

$0.22

50-day MA

$8.14

200-day MA

$11.75

Beta

0.91

Analyst view

Analysts rate GT Biopharma Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $75.00.

Shareholding

Insiders

5.71%

Institutions

4.66%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.77%
Geode Capital Management, LLC	1.15%
Vanguard Fiduciary Trust Co	0.88%
Everhart Financial Group, Inc.	0.39%
SRS Capital Advisors Inc	0.37%
Opal Wealth Advisors, LLC	0.32%
Seacrest Wealth Management, LLC	0.20%
KITCHING PARTNERS LLC	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GT Biopharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.